Physician profile

Mohammad Ali

Internal Medicine · Danville, PA

NPI 1033350392

$601.07

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$325.18
Education$213.98

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Insmed, INC. $197.76 2023-2024 Arikayce
Astellas Pharma US INC $144.97 2023 Cresemba
Abbvie INC. $92.72 2021-2024 Avycaz
Gilead Sciences, INC. $72.88 2023-2024
Aimmune Therapeutics, INC. $31.96 2023
Merck Sharp & Dohme LLC $18.75 2024 Delstrigo, Pifeltro
Aveo Pharmaceuticals, INC. $15.74 2022
Theratechnologies INC. $13.77 2020
Novartis Pharmaceuticals Corporation $12.52 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mohammad Ali

$601.07

in general payments reported 2019-2025

Years
2019-2024
Top company
Insmed, INC.

https://glasscript.com/doctor/1104668/mohammad-ali

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.